Persistent cutaneous hyperpigmentation due to hydroxychloroquinone one year after therapy discontinuation.
Hydroxychloroquine (HCQ) was initially indicated for the treatment of malaria, but more recently its anti-inflammatory and immune modulating properties have been utilized for treatment of multiple dermatologic and rheumatologic diseases. Mucocutaneous bluish-gray dyschromia is a rare side effect with HCQ and little information exists regarding its duration after drug discontinuation. The few existing case reports primarily describe small focal areas of discoloration. More extensive dyschromia has very rarely been reported with HCQ. We report a case of HCQ induced dyschromia diffusely involving the extremities, with minimal resolution one year after treatment discontinuation.
Morrison
L Katie
LK
Center for Clinical Studies, Houston, Texas, USA.
Nordlund
James J
JJ
Heffernan
Michael P
MP
D000368:Aged; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage / Q000009:adverse effects*; D017495:Hyperpigmentation / Q000139:chemically induced*; D013997:Time Factors
D006886:Hydroxychloroquine